Sofinnova Investments

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with additional offices in La Jolla, California; Montreal, Quebec; and Tokyo, Japan. It backs early to later-stage startups in life sciences and information technology across the United States and Europe, focusing on West Coast U.S. and developed European markets. In life sciences, the firm pursues clinical-stage pharmaceutical, biotechnology and medical technology companies, including drug discovery platforms and entities addressing diseases with unmet medical needs, covering therapeutic areas such as oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it funds product-oriented software, enterprise software, service-provider software, and telecommunications infrastructure. Seed investments in both domains typically range from 0.1 million to 1 million, with initial rounds for technology commonly 3-5 million and life science rounds 5-15 million; total commitments generally span 5-15 million for tech and 15-30 million for life sciences. The firm seeks board seats when leading or co-leading early-stage investments.

Nathalie Auber

CFO and Partner

Sarah Bhagat

General Partner

Chris Carpenter Ph.D

Executive Partner

Robert Carr

Managing Director

Eric Delbridge MD

Portfolio Manager and Partner, Public Equity

Past deals in Bermuda

Kiniksa Pharmaceuticals International

Series C in 2018
Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company has a diverse pipeline of clinical-stage product candidates, including Rilonacept, which is undergoing Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, currently in Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Kiniksa also has preclinical candidates, such as KPL-404, which targets the CD40/CD40L interaction in immune responses. Additionally, the company is collaborating with Kite Pharma to explore the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa Pharmaceuticals aims to address multiple autoimmune and autoinflammatory conditions through its innovative approaches.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.